Navigation Links
FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
Date:12/10/2007

New class of ApoA-I/HDL drugs to reverse atherosclerosis enters the clinic

TSX Exchange Symbol: RVX

CALGARY, Dec. 10 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administration (FDA) to initiate a Phase 1a clinical trial of oral RVX-208 in the USA. RVX-208 is a novel first-in-class small molecule that increases the production of ApoA-I and HDL. ApoA-I is regarded as the critical cardioprotective protein for the treatment of cardiovascular diseases.

The Phase I clinical trial is taking place at a leading US contract research organization. The trial consist of three arms, an ascending single dose, a fed and fasted dose effect study, and a 7-day ascending multiple dose that will enroll a total of 70-80 healthy volunteers. The primary objective of the trial is to evaluate oral RVX-208 in healthy adult subjects for safety, tolerability, and pharmacokinetics. Results from this Phase 1a trial will be used for optimizing dosing for future trials including our Phase 1b trial.

Gregory S. Wagner, PhD, Senior Vice President, Preclinical Development of Resverlogix, stated that, "RVX-208 possesses a very favorable pharmacological and pharmaceutical profile. This compound is an excellent choice to be the first drug candidate from our preclinical pipeline, our research and development team has worked aggressively to rapidly advance it into clinical development."

"This field has been developing for 50 years. In multiple human and animal studies over-expression or repeated infusion of ApoA-I inhibit progression and induce regression of atherosclerosis in both animals and humans," stated Dr. Jan Johansson, MD, PhD. Senior Vice President of Clinical Affairs of Resverlogix. "We have identified a way to increase the endogenous production of ApoA-I via a small molecule drug. The initiation of this clinical trial is a milestone for the fi
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Resverlogix is Presenting at IAS HDL Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... NJ (PR Web) July 21, 2014 (PRWEB) July ... Center for Biomaterials, at Rutgers University. , ... information and ideas across the full spectrum of ... on selected research and development topics that represent ... Activities have been programmed to:, ...
(Date:7/22/2014)... phylum so full of mean little creatures, the yellow-colored Ormia ... -- at least to crickets. Native to the southeastern U.S. ... sort of parasite. It swoops onto the back of a ... its wicked brood to invade, kill and consume the cricket ... possible without the fly,s ability to find a cricket -- ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... July 22, 2014   BioTE Medical , ... natural, bio-identical hormone pellets, today announced the addition ... the company.   Dr. Rouzier is joining the BioTE ... Dr. Rouzier was residency trained in ... is a board certified emergency physician still practicing ...
Breaking Biology Technology:The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
... plc (LSE: SHP, NASDAQ: SHPGY ) announces ... Court of the Southern District of,New York against Mylan ... for infringement of Shire,s,patent: U.S. Patent No. 5,968,976 (",976 ... filed in response to an Abbreviated New Drug Application,("ANDA") ...
... 20 A new, innovative study,shows that a ... plus dexamethasone not only prevents chemotherapy-induced nausea,and vomiting ... oncology,patients. Data presented today at the ESMO Symposium ... New data presented today at ...
Cached Biology Technology:Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 2Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 2Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 3Palonosetron Warrants Adequate Caloric Intake in Oncology Patients Receiving High Emetogenic Chemotherapy 4
(Date:7/23/2014)... International Journal of Fuzzy Systems ( IJFS ), ... (TFSA). The cooperation will allow the journal to expand ... The International Journal of Fuzzy Systems is ... theory, design and application of fuzzy systems, soft computing ... hardware to software. Launched in 1999, the quarterly journal ...
(Date:7/23/2014)... German . , ... of which might be very different from ours. Some ... by sunlight in the atmosphere to calibrate their orientation ... Ornithology in Seewiesen, Germany, and Queen,s University Belfast have ... mammal, the greater mouse-eared bat, has the capability to ...
(Date:7/23/2014)... YORK, NY -- The New York Stem Cell Foundation ... to develop stem cell resources to investigate and explore ... Batten disease, a fatal illness affecting children. , NYSCF ... from skin samples of young people affected by juvenile ... cell lines are produced by artificially "turning back the ...
Breaking Biology News(10 mins):Bats use the evening sky's polarization pattern for orientation 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 2NYSCF partners with Beyond Batten Disease Foundation to fight juvenile Batten disease 3
... CHAMPAIGN, Ill. University of Illinois researchers are using ... weightiest questions in biology the relationship between cell mass ... computer engineering and bioengineering professor Rashid Bashir, published its results ... the National Academy of Sciences . "It,s merging micro-scale ...
... , LA JOLLA, CA-Fisetin, a naturally occurring compound ... slows the onset of motor problems and delays ... to researchers at the Salk Institute for Biological ... of Human Molecular Genetics , sets the ...
... ovarian cancer but new research from the Centenary Institute has ... new way that can break the resistance mechanism. Published ... (FTY720) had a potent effect in human ovarian cancer cells, ... chemotherapeutic drug currently available for the treatment of ovarian cancer. ...
Cached Biology News:Microsensors offer first look at whether cell mass affects growth rate 2Natural compound shows promise against Huntington's disease 2Natural compound shows promise against Huntington's disease 3New treatment to overpower drug resistance in ovarian cancer 2
Control primers and template for 5kb and 15 kb products....
Carrier Serum...
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: